Allergan plc / Kythera Biopharmaceuticals, Inc.

Submental Fullness (Aesthetic Medicine)

$300M Analyst peak sales estimate (Kybella, US)

Disease Overview

Submental fullness — colloquially 'double chin' — is excess subcutaneous fat under the jaw that resists diet and exercise. An American Society for Dermatologic Surgery survey found roughly two-thirds of US adults are bothered by it, making it one of the largest unmet aesthetic targets and historically addressable only through liposuction or surgical lipectomy.

Competitive Landscape

Before Kybella, the submental fullness market was almost entirely procedural — submental liposuction, surgical lipectomy, and cryolipolysis (CoolSculpting/CoolMini from Zeltiq, FDA-cleared for submental in 2015). Kybella's April 2015 FDA approval as the first injectable adipocytolytic created a brand-new pharmacologic category, and Allergan's October 2015 acquisition was framed as a bolt-on to the company's facial aesthetics franchise alongside Botox, Juvederm, and Voluma. BMO Capital's David Maris argued Allergan needed to control all 'potentially game-changing' aesthetic technologies to defend its category leadership, with sell-side analysts pegging Kybella peak US sales at ~$300M. Post-acquisition uptake disappointed: injector adoption was slowed by patient swelling/recovery time and competition from non-invasive cryolipolysis, and Kybella never reached the $300M peak forecast. The deal also brought setipiprant (KYTH-105), a CRTh2 antagonist explored for male pattern baldness — a long-shot pipeline asset that did not advance to commercial product.